Bure Equity AB (publ)

Bure Equity AB (publ) is a Sweden-based investment company focused on long-term active ownership to develop and realize the potential of portfolio companies, creating sustainable value growth for shareholders. Founded in 1992 and listed on Nasdaq Stockholm since 1993, it maintains a diversified portfolio across various sectors and development phases, including technology (45%), medtech (35%), industry, finance, and others. The company holds interests in approximately 11 portfolio companies, with around 80% listed and 17% unlisted, such as Mycronic for electronics production equipment, MedCap in life sciences, Vitrolife for fertility solutions, and XVIVO Perfusion for organ preservation. Bure acts as a responsible, situation-based investor with a strong ownership philosophy emphasizing deep commitment, board representation, strategic guidance, and financial support. Headquartered in Stockholm, it prioritizes professionalism, determination, and respect while adhering to the Swedish Code of Corporate Governance to build resilient businesses and deliver competitive long-term returns.